APRE compared with PYPD: revenue, margins and what each company keeps, and the suppliers and customers both name

APREAprea Therapeutics, Inc.

Mkt capRevenueRevenue

PYPDPolyPid Ltd.

Mkt capRevenueRevenue

Compare

APREAprea Therapeutics, Inc.

PYPDPolyPid Ltd.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

rebased to 0%

APRE, solidPYPD, dashed

Supply-chain overlap

Revenue flow

APRE: latest quarter is a loss; flow not drawable. PYPD: latest quarter not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

No disclosed counterparties: APRE, PYPD.

Role chip = supplier or customerSource: SEC EDGAR

APREAprea Therapeutics, Inc.

0.48▼−2.11%· post 0.48

Mkt cap$6.1MRevenue$3,337Q4 FY25Revenue$285,759FY25

PYPDPolyPid Ltd.

5.49▼−1.76%· post 5.45

ClosedOct 30 '26

Mkt cap$88.1MRevenue—Revenue—

Compare

ClosedOct 30 '26

APREAprea Therapeutics, Inc.

PYPDPolyPid Ltd.

0.48▼−2.11%post 0.48

Price

5.49▼−1.76%post 5.45

$6.1M

Mkt cap

$88.1M

Q4 FY25$3,337

Revenue

—

FY25$285,759

Revenue

—

APRE0.48▼−2.11%vsPYPD5.49▼−1.76%ClosedOct 30 '26